Novel reversible inhibitor of interleukin-2 (IL-2)

Vitamin D analogue, showing significant in vitro and in vivo antitumor activity.

Potent and selective Candida albicans N-myristoyltransferase (CaNmt) inhibitor, exhibiting antifungal activity in vivo

Potent and selective Candida albicans N-myristoyltransferase (CaNmt) inhibitor

NMDA receptor antagonist , specifically suppressing the severe autoimmune phenotypes of chs3-2D (chilling sensitive 3, 2D), including the arrested growth morphology and heightened PR (Pathogenesis Related) gene expression

Novel NR2B selective, non-competitive, voltage-independent antagonist

Selective, non-competitive Metabotropic_glutamate_receptor>mGlu2 antagonist

Competitive AMPA receptor antagonist

ADAM17-selective inhibitor

Potent protein kinase C (PKC) inhibitor

Potent and selective antagonist of NMDA glutamate receptors containing the NR2B subunit

Selective alpha1A/1L-adrenoceptor partial agonist

Selective antagonist of NMDA receptors NR2B subunits

Novel potent and specific RNA-binding ligand, targeting riboswitches and other RNAs at proximal subsites

Potent, reversible, non-carbonyl inhibitor of fatty acid amide hydrolase (FAAH)

The first irreversible covalent MPS1 inhibitor, targeting a poorly conserved cysteine in the kinase's hinge region

Novel Fluorescent ER-Tracker dye, showing potent cytotoxic activity on several types of cancer cells, being accumulated into the endoplasmic reticulum (ER) as highlighted by its colocalization

Novel MOR agonist

Promising pro-apoptotic agent, showing activity on various cancer cell lines

Novel gastrocolokinetic ghrelin agonist, approximately sixfold greater potency than natural ghrelin

Novel potent and highly selective GPR6 inverse agonist, inhibiting GPR6 cAMP signalling in TR-FRET assays with a EC50 = 16 nM and >100 fold selectivity against GPR3 and GPR12

Novel selective inhibitor of activated fibroblasts, inhibiting the enhanced migration of fibroblasts cocultured with cancer cells by binding to β-arrestin1 and interfering with β-arrestin1-mediated cofilin signaling pathways

Novel potent and selective SIRT2 inhibitor, increasing the acetylation level of eukaryotic translation initiation factor 5A (eIF5A) and reducing cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression

Natural selective inhibitor of protein tyrosine phosphatases (PTPases)

Novel inhibitor of dengue virus NS5 RNA-dependent RNA polymerase (RdRp), inhibiting the DENV type 2 (DENV2) RdRp activities

Novel potent Liver Receptor Homolog-1 (LRH-1) modulator

Highly selective α4β2 subtype nicotinic receptor agonist

Novel peroxisome proliferator-activated receptor gamma (PPARgamma) agonist

Novel IAP-based selective RIPK2 degrader

First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific inhibitor